US FDA approves updated COVID vaccines for 2026-27 season

• Four COVID vaccines approved: Moderna's mNEXSPIKE and Spikevax, Pfizer-BioNTech's Comirnaty (all mRNA-based), and Novavax-Sanofi's protein-based shot which requires longer manufacturing time
• The XFG variant target represents a shift from the 2025-26 season vaccines, which targeted the LP.8.1 subvariant of the JN.1 strain
• Current COVID strain data from the CDC is unavailable due to low sequencing submissions, though all manufacturers confirmed they can produce updated shots in time for the 2026-27 immunization season

Summary: FDA Approves Updated COVID Vaccines for 2026-27 Season

The U.S. Food and Drug Administration has approved updated COVID-19 vaccines from Moderna, Novavax-Sanofi, and Pfizer-BioNTech for the 2026-27 immunization season, following an advisory panel's recommendation to target the dominant XFG variant.

Key Companies and Products:

• Moderna: mNEXSPIKE and Spikevax (mRNA-based vaccines)
• Pfizer-BioNTech: Comirnaty (mRNA-based vaccine)
• Novavax-Sanofi: Protein-based vaccine (requires longer manufacturing time)

Important Details:

• In May, the FDA advisory committee voted 8-1 in favor of targeting the XFG variant for the upcoming season
• All manufacturers confirmed they can produce the updated vaccines in time for the 2026-27 campaign
• For the current 2025-26 season, vaccines targeted the LP.8.1 subvariant of the JN.1 strain
• Four COVID vaccine formulations are now approved for use in the United States

Market Context:

The CDC's COVID dashboard currently shows limited new strain data due to low sequencing submissions, making the advisory panel's variant selection particularly significant for manufacturers' production planning. The approval ensures continuity in the U.S. vaccine supply chain and provides clarity for pharmaceutical companies to proceed with manufacturing.

This development maintains the established annual update cycle for COVID vaccines, similar to seasonal flu shots, and confirms the ongoing commercial opportunity for all three vaccine manufacturers in the U.S. market.